Cárdenas CL, Castillo CLM

Language: Spanish
References: 15
Page: 142-149
PDF size: 441.23 Kb.

ABSTRACT

Nowadays, botulinum toxin Type A is used for various disease treatment with hyperactivity muscular located and cosmetic using. botulinum toxin Type A is conformed to a protein nucleus of 150 kDa associated to a complex of 6 auxiliary non-toxic proteins. In the response to chronic treatment with botulinum toxin Type A a decrease of interlude time for toxin application has been described, which can be expressed as an effect decrease of botulinum toxin Type A. Immune mechanism was identified by a search, as well as main molecules involved in development of tolerance immune versus botulinum toxin Type A. Systematic research was performed in data bases as: Pubmed, Scielo, Imbiomed. Basics and clinical research articles published after 2000 were consulted. Focusing in publications with 4 or less years since their publication. The reduction of periodicity of dosage of BoNTA is induced by immune tolerance, it is principally mediated by major histocompatibility, antigen CD19 and interleukin-6. The immune tolerance induce an increases of dosage required for establish an effective treatment with botulinum toxin Type A; however, this does not mean a botulinum toxin dependence. Development of immune tolerance to treatments with BoNTA induces a low effectiveness of chronic treatment and evidence the necessity to researching new treatments that reduce the immune tolerance of botulinum toxin Type A. Meaning an effectivity reduces of a treatment to chronic diseases.

REFERENCES

1. Atassi MZ. Basic immunological aspects of botulinum toxin therapy. Movement disorders : official journal of the Movement Disorder Society. 2004;19 Suppl 8:S68-84.

2. Morales MV PK, Zuluaga A. . Conocimientos básicos sobre la toxina botulínica para una utilización terapéutica segura. Rev Col Med Fis Rehab. 2013;25(2):12.

3. Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2012;26(2):e1-9.

4. Dressler D. Five-year experience with incobotulinumtoxinA (Xeomin((R)) ): the first botulinum toxin drug free of complexing proteins. European journal of neurology : the official journal of the European Federation of Neurological Societies. 2012;19(3):385-9.

5. Oshima M, Deitiker PR, Jankovic J, Duane DD, Aoki KR, Atassi MZ. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. Journal of neuroimmunology. 2011;240-241:121-8.

6. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nature structural biology. 1998;5(10):898-902.

7. Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics : targets & therapy. 2010;4:325-32.

8. Maggio M, Guralnik JM, Longo DL, Ferrucci L. Interleukin-6 in aging and chronic disease: a magnificent pathway. The journals of gerontology Series A, Biological sciences and medical sciences. 2006;61(6):575-84.

9. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. The Biochemical journal. 2003;374(Pt 1):1-20.

10. Saavedra PG VG, Gonzáles LA. Interleucina-6: ¿amiga o enemiga? Bases para comprender su utilidad como objetivo terapéutico. Iatreia. 2011;24(2):9.

11. Xu Y, Fairfax K, Light A, Huntington ND, Tarlinton DM. CD19 differentially regulates BCR signalling through the recruitment of PI3K. Autoimmunity. 2014;47(7):430-7.

12. Otero DC, Rickert RC. CD19 function in early and late B cell development. II. CD19 facilitates the pro-B/pre-B transition. Journal of immunology. 2003;171(11):5921-30.

13. Depoil D, Fleire S, Treanor BL, Weber M, Harwood NE, Marchbank KL, et al. CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand. Nature immunology. 2008;9(1):63-72.

14. Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. Journal of neural transmission. 2013;120(2):275-90.

15. 15. Atassi MZ, Oshima M, Dolimbek BZ, Aoki KR. Antibody and T cell recognition of the light chain of botulinum neurotoxin A in two high-responder mouse strains. Immunobiology. 2012;217(1):1-7.